[The impact of human serum immunoglobulin treatment of refractory immune thrombocytopenic purpura. Analysis].
OBJECTIVE
To observe the impact of human serum immunoglobulin treatment of refractory immune thrombocytopenic purpura in clinical efficacy.


METHODS
220 patients met the diagnostic criteria of refractory immune thrombocytopenic purpura, patients were randomly divided into treatment group and control group, 110 patients in each group. Groups were given prednisolone tablets 1 mg/ (kg x d), 2 times/d, oral, taking for 2 weeks, and than gradually reducing, the maintenance to be suspended; all-trans retinoic acid, each 10 mg, 3 times a day, oral. On this basis, the treatment group increases the employing blood immunoglobulin 400 mg/ (kg x d) infusion qd for 7 days. The two groups are 4 weeks for the course of treatment, a therapeutic effect after treatment.


RESULTS
The total effective treatment group and control group were 94.56%, 80.91%, statistically significant differences between two groups (P < 0.05). Treatment serum IL-2, IFN-gamma, IL-4, IL-10, TGF-beta1, significant differences compared to other indicators (p < 0.05). Platelet counts after treatment, the rates of increase, effective hemostasis time of the treatment group compared with the control group, significant difference (p < 0.05).


CONCLUSIONS
The impact of human serum immunoglobulin treatment of refractory immune thrombocytopenic purpura significantly shorten the bleeding time, platelet and platelet rise-time return to normal time.
Luo
Fang
F
People's Liberation Army, No. 181 Hospital, Guilin, China.
Jiang
Chun-feng
CF
Lin
Shu-sen
SS
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000097:blood; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007136:Immunoglobulins / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D016207:Cytokines; D007136:Immunoglobulins